Compare Gilead Sciences, Inc. (GILD) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Natera Inc. Common Stock — how do they compare? Gilead Sciences, Inc. trades at $155.6 (market cap $190.38B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Gilead Sciences, Inc. is far larger — about 3.3× Natera Inc. Common Stock's market cap, and Gilead Sciences, Inc. pays a 2.14% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 112 Days and Natera Inc. Common Stock for 0 Days on average.
| GILD | NTRA | |
|---|---|---|
Market Cap | $190.38B | $57.03B |
Volume | 5,758,183 | 1,131,157 |
Sector | Health | Health |
52-Week High | $155.80 | $425.64 |
52-Week Low | $117.85 | $179.42 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $213.45B | $56.18B |
Dividend Yield | 2.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.92, down 1.67% on the day, with strong analyst support (67% buy ratings) and a $153.13 consensus price target. Recent quarterly earnings beat expectations despite a Q2 loss, while revenue growth remains steady. Technical indicators show a bullish trend with support at $147-149 and resistance at $152-154. The company continues expanding HIV treatment access through recent PAHO partnerships.
GILD presents a mixed fundamental picture with strong revenue growth but negative net margins. The stock offers upside to analyst targets but faces execution risks in oncology pipeline development and competitive pressures. Recent institutional selling and high debt levels warrant monitoring, though expanding HIV franchise provides stable cash flow foundation.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
